Abstract
The androgen receptor (AR) mediates the growth-stimulatory effects of androgens in prostate cancer cells. Identification of androgen-regulated genes in prostate cancer cells is therefore of considerable importance for defining the mechanisms of prostate-cancer development and progression. Although several studies have used microarrays to identify AR-regulated genes in prostate cancer cell lines and in prostate tumours, we present here the results of gene expression microarray profiling of the androgen-responsive LNCaP prostate-cancer cell line treated with R1881 for the identification of androgen-regulated genes. We show that the expression of 319 genes is stimulated by 24 h after R1881 addition, with a similar number (300) of genes being significantly repressed. Expression of the upregulated genes, as well as of 60 of the most robustly downregulated genes, was carried out using quantitative RT–PCR (Q-RT–PCR) over a time-course of R1881 treatment from 0 to 72 h. Q-RT–PCR was also carried out following treatment with other AR agonists (dihydrotestosterone, estradiol and medroxyprogesterone) and antagonists (cyproterone acetate, hydroxyflutamide and bicalutamide). This study provides a comprehensive analysis of androgen-regulated gene expression in the LNCaP prostate cancer cell line, and identifies a number of androgen-regulated genes, not described previously, as candidates for mediating androgen responses in prostate cancer cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Abdulkadir SA, Magee JA, Peters TJ, Kaleem Z, Naughton CK, Humphrey PA et al. (2002). Conditional loss of Nkx3.1 in adult mice induces prostatic intraepithelial neoplasia. Mol Cell Biol 22: 1495–1503.
Agoulnik IU, Weigel NL . (2006). Androgen receptor action in hormone-dependent and recurrent prostate cancer. J Cell Biochem 99: 362–372.
Akashi T, Koizumi K, Nagakawa O, Fuse H, Saiki I . (2006). Androgen receptor negatively influences the expression of chemokine receptors (CXCR4, CCR1) and ligand-mediated migration in prostate cancer DU-145. Oncol Rep 16: 831–836.
Arnold JT, Liu X, Allen JD, Le H, McFann KK, Blackman MR . (2007). Androgen receptor or estrogen receptor-beta blockade alters DHEA-, DHT-, and E(2)-induced proliferation and PSA production in human prostate cancer cells. Prostate 67: 1152–1162.
Brinkmann AO, Blok LJ, de Ruiter PE, Doesburg P, Steketee K, Berrevoets CA et al. (1999). Mechanisms of androgen receptor activation and function. J Steroid Biochem Mol Biol 69: 307–313.
Brooke GN, Parker MG, Bevan CL . (2008). Mechanisms of androgen receptor activation in advanced prostate cancer: differential co-activator recruitment and gene expression. Oncogene 27: 2941–2950.
Burmester JK, Suarez BK, Lin JH, Jin CH, Miller RD, Zhang KQ et al. (2004). Analysis of candidate genes for prostate cancer. Hum Hered 57: 172–178.
Busillo JM, Benovic JL . (2007). Regulation of CXCR4 signaling. Biochim Biophys Acta 1768: 952–963.
Carter HB, Coffey DS . (1990). The prostate: an increasing medical problem. Prostate 16: 39–48.
Chen H, Nandi AK, Li X, Bieberich CJ . (2002). NKX-3.1 interacts with prostate-derived Ets factor and regulates the activity of the PSA promoter. Cancer Res 62: 338–340.
Cheng I, Stram DO, Penney KL, Pike M, Le Marchand L, Kolonel LN et al. (2006). Common genetic variation in IGF1 and prostate cancer risk in the Multiethnic Cohort. J Natl Cancer Inst 98: 123–134.
Chintharlapalli S, Burghardt R, Papineni S, Ramaiah S, Yoon K, Safe S . (2005). Activation of Nur77 by selected 1,1-bis(3′-indolyl)-1-(p-substituted phenyl)methanes induces apoptosis through nuclear pathways. J Biol Chem 280: 24903–24914.
Chipuk JE, Cornelius SC, Pultz NJ, Jorgensen JS, Bonham MJ, Kim SJ et al. (2002). The androgen receptor represses transforming growth factor-beta signaling through interaction with Smad3. J Biol Chem 277: 1240–1248.
Cunha GR, Donjacour AA, Cooke PS, Mee S, Bigsby RM, Higgins SJ et al. (1987). The endocrinology and developmental biology of the prostate. Endocr Rev 8: 338–362.
Davies P, Eaton CL . (1991). Regulation of prostate growth. J Endocrinol 131: 5–17.
Dehm SM, Tindall DJ . (2006). Molecular regulation of androgen action in prostate cancer. J Cell Biochem 99: 333–344.
Dennis Jr G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC et al. (2003). DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4: P3.
Doesburg P, Kuil CW, Berrevoets CA, Steketee K, Faber PW, Mulder E et al. (1997). Functional in vivo interaction between the amino-terminal, transactivation domain and the ligand binding domain of the androgen receptor. Biochemistry 36: 1052–1064.
Feldman BJ, Feldman D . (2001). The development of androgen-independent prostate cancer. Nat Rev Cancer 1: 34–45.
Furr BJ, Tucker H . (1996). The preclinical development of bicalutamide: pharmacodynamics and mechanism of action. Urology 47: 13–25 discussion 29–32.
Gottlieb B, Beitel LK, Wu JH, Trifiro M . (2004). The androgen receptor gene mutations database (ARDB): 2004 update. Hum Mutat 23: 527–533.
Guo Y, Jacobs SC, Kyprianou N . (1997). Down-regulation of protein and mRNA expression for transforming growth factor-beta (TGF-beta1) type I and type II receptors in human prostate cancer. Int J Cancer 71: 573–579.
Guo Y, Kyprianou N . (1998). Overexpression of transforming growth factor (TGF) beta1 type II receptor restores TGF-beta1 sensitivity and signaling in human prostate cancer cells. Cell Growth Differ 9: 185–193.
Guo Y, Kyprianou N . (1999). Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis. Cancer Res 59: 1366–1371.
Heemers HV, Verhoeven G, Swinnen JV . (2006). Androgen activation of the sterol regulatory element-binding protein pathway: current insights. Mol Endocrinol 20: 2265–2277.
Hodgson MC, Astapova I, Hollenberg AN, Balk SP . (2007). Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors. Cancer Res 67: 8388–8395.
Huang da W, Sherman BT, Tan Q, Collins JR, Alvord WG, Roayaei J et al. (2007). The DAVID Gene Functional Classification Tool: a novel biological module-centric algorithm to functionally analyze large gene lists. Genome Biol 8: R183.
Huber W, von Heydebreck A, Sultmann H, Poustka A, Vingron M . (2002). Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics 18: S96–S104.
Ke N, Claassen G, Yu DH, Albers A, Fan W, Tan P et al. (2004). Nuclear hormone receptor NR4A2 is involved in cell transformation and apoptosis. Cancer Res 64: 8208–8212.
Kim MJ, Bhatia-Gaur R, Banach-Petrosky WA, Desai N, Wang Y, Hayward SW et al. (2002). Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis. Cancer Res 62: 2999–3004.
Kwok WK, Ling MT, Lee TW, Lau TC, Zhou C, Zhang X et al. (2005). Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res 65: 5153–5162.
Lau KM, LaSpina M, Long J, Ho SM . (2000). Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. Cancer Res 60: 3175–3182.
Lee MY, Moon JS, Park SW, Koh YK, Ahn YH, Kim KS . (2009). KLF5 enhances SREBP-1 action in androgen-dependent induction of fatty acid synthase in prostate cancer cells. Biochem J 417: 313–322.
Lu NZ, Wardell SE, Burnstein KL, Defranco D, Fuller PJ, Giguere V et al. (2006). International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. Pharmacol Rev 58: 782–797.
Masiello D, Cheng S, Bubley GJ, Lu ML, Balk SP . (2002). Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J Biol Chem 277: 26321–26326.
McConnell JD . (1991). Physiologic basis of endocrine therapy for prostatic cancer. Urol Clin North Am 18: 1–13.
Myung SJ, Rerko RM, Yan M, Platzer P, Guda K, Dotson A et al. (2006). 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci USA 103: 12098–12102.
Nelson PS, Clegg N, Arnold H, Ferguson C, Bonham M, White J et al. (2002). The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci USA 99: 11890–11895.
Oettgen P, Finger E, Sun Z, Akbarali Y, Thamrongsak U, Boltax J et al. (2000). PDEF, a novel prostate epithelium-specific ets transcription factor, interacts with the androgen receptor and activates prostate-specific antigen gene expression. J Biol Chem 275: 1216–1225.
Ono T, Losada A, Hirano M, Myers MP, Neuwald AF, Hirano T . (2003). Differential contributions of condensin I and condensin II to mitotic chromosome architecture in vertebrate cells. Cell 115: 109–121.
Qi W, Gao S, Wang Z . (2008). Transcriptional regulation of the TGF-beta1 promoter by androgen receptor. Biochem J 416: 453–462.
Rae JM, Johnson MD, Cordero KE, Scheys JO, Larios JM, Gottardis MM et al. (2006). GREB1 is a novel androgen-regulated gene required for prostate cancer growth. Prostate 66: 886–894.
Shang Y, Myers M, Brown M . (2002). Formation of the androgen receptor transcription complex. Mol Cell 9: 601–610.
Shanmugam I, Cheng G, Terranova PF, Thrasher JB, Thomas CP, Li B . (2007). Serum>glucocorticoid-induced protein kinase-1 facilitates androgen receptor-dependent cell survival. Cell Death Differ 14: 2085–2094.
Shilatifard A, Duan DR, Haque D, Florence C, Schubach WH, Conaway JW et al. (1997). ELL2, a new member of an ELL family of RNA polymerase II elongation factors. Proc Natl Acad Sci USA 94: 3639–3643.
Simone F, Luo RT, Polak PE, Kaberlein JJ, Thirman MJ . (2003). ELL-associated factor 2 (EAF2), a functional homolog of EAF1 with alternative ELL binding properties. Blood 101: 2355–2362.
Smyth GK . (2004). Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article 3.
Sobel RE, Sadar MD . (2005). Cell lines used in prostate cancer research: a compendium of old and new lines–part 1. J Urol 173: 342–359.
Steketee K, Timmerman L, Ziel-van der Made AC, Doesburg P, Brinkmann AO, Trapman J . (2002). Broadened ligand responsiveness of androgen receptor mutants obtained by random amino acid substitution of H874 and mutation hot spot T877 in prostate cancer. Int J Cancer 100: 309–317.
Storlazzi CT, Mertens F, Nascimento A, Isaksson M, Wejde J, Brosjo O et al. (2003). Fusion of the FUS and BBF2H7 genes in low grade fibromyxoid sarcoma. Hum Mol Genet 12: 2349–2358.
Takahashi Y, Perkins SN, Hursting SD, Wang TT . (2007). 17beta-Estradiol differentially regulates androgen-responsive genes through estrogen receptor-beta- and extracellular-signal regulated kinase-dependent pathways in LNCaP human prostate cancer cells. Mol Carcinog 46: 117–129.
Tamura K, Furihata M, Tsunoda T, Ashida S, Takata R, Obara W et al. (2007). Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. Cancer Res 67: 5117–5125.
Taplin ME, Balk SP . (2004). Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem 91: 483–490.
Veldscholte J, Berrevoets CA, Brinkmann AO, Grootegoed JA, Mulder E . (1992a). Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry 31: 2393–2399.
Veldscholte J, Berrevoets CA, Ris-Stalpers C, Kuiper GG, Jenster G, Trapman J et al. (1992b). The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol 41: 665–669.
Wolf I, O′Kelly J, Rubinek T, Tong M, Nguyen A, Lin BT et al. (2006). 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res 66: 7818–7823.
Xiao W, Zhang Q, Jiang F, Pins M, Kozlowski JM, Wang Z . (2003). Suppression of prostate tumor growth by U19, a novel testosterone-regulated apoptosis inducer. Cancer Res 63: 4698–4704.
Ying J, Srivastava G, Hsieh WS, Gao Z, Murray P, Liao SK et al. (2005). The stress-responsive gene GADD45G is a functional tumor suppressor, with its response to environmental stresses frequently disrupted epigenetically in multiple tumors. Clin Cancer Res 11: 6442–6449.
Yoon HG, Wong J . (2006). The corepressors silencing mediator of retinoid and thyroid hormone receptor and nuclear receptor corepressor are involved in agonist- and antagonist-regulated transcription by androgen receptor. Mol Endocrinol 20: 1048–1060.
Yuen HF, Chua CW, Chan YP, Wong YC, Wang X, Chan KW . (2006). Id proteins expression in prostate cancer: high-level expression of Id-4 in primary prostate cancer is associated with development of metastases. Mod Pathol 19: 931–941.
Zha S, Ferdinandusse S, Denis S, Wanders RJ, Ewing CM, Luo J et al. (2003). Alpha-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancer. Cancer Res 63: 7365–7376.
Zha S, Ferdinandusse S, Hicks JL, Denis S, Dunn TA, Wanders RJ et al. (2005). Peroxisomal branched chain fatty acid beta-oxidation pathway is upregulated in prostate cancer. Prostate 63: 316–323.
Acknowledgements
We are grateful to the members of the group for advice and support. Our particular thanks go to Drs Greg Brooke and Charlotte Bevan for discussions, and to Dr Lev Soinov for aiding the analysis of the microarray data. This work was carried out through the support of the Joron trust, Hammersmith Hospital trustees, Prostate Cancer Charity and Cancer Research UK.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc)
Rights and permissions
About this article
Cite this article
Ngan, S., Stronach, E., Photiou, A. et al. Microarray coupled to quantitative RT–PCR analysis of androgen-regulated genes in human LNCaP prostate cancer cells. Oncogene 28, 2051–2063 (2009). https://doi.org/10.1038/onc.2009.68
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2009.68
Keywords
This article is cited by
-
Identification of valid reference genes for mRNA and microRNA normalisation in prostate cancer cell lines
Scientific Reports (2018)
-
Stem cell and neurogenic gene-expression profiles link prostate basal cells to aggressive prostate cancer
Nature Communications (2016)
-
Regulation of several androgen-induced genes through the repression of the miR-99a/let-7c/miR-125b-2 miRNA cluster in prostate cancer cells
Oncogene (2014)
-
Transcription signatures encoded by ultraconserved genomic regions in human prostate cancer
Molecular Cancer (2013)
-
MicroRNA-185 suppresses proliferation, invasion, migration, and tumorigenicity of human prostate cancer cells through targeting androgen receptor
Molecular and Cellular Biochemistry (2013)